Volume 13, Issue 1 ( March 2021 2021)                   Iranian Journal of Blood and Cancer 2021, 13(1): 11-16 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Al-Kahiry W M, Rabie M A F, Sharshira H M, Ghanem A M, El-gammal M M, Mikhael I L. Prognostic Impact of Interleukin-10 in Patients with Chronic Lymphocytic Leukemia. Iranian Journal of Blood and Cancer 2021; 13 (1) :11-16
URL: http://ijbc.ir/article-1-998-en.html
1- Department of Hematology, Faculty of Medicine and Health Sciences, University of Aden, Yemen , kahiry13@gmail.com
2- Department of Medical Laboratory Technology, Pharos University in Alexandria, Egypt
3- Department of Hematology, Medical Research Institute, University of Alexandria, Egypt
Abstract:   (2223 Views)

Background: Several markers are investigated for prognostic purpose in CLL patients among which interleukin-10 (IL-10) is under more investigation. We aimed to study IL-10 level in a group of newly diagnosed patients with CLL in a single center in Alexandria, Egypt.
Methods: In this study, 80 newly diagnosed patients with CLL referring to Hematology Department of the Medical Research Institute of Alexandria University, Egypt, and a control group including 40 healthy volunteers were included. ZAP-70 was determined by flowcytometry and serum IL-10 concentration was measured using IL-10 sandwich ELISA method.
Results: Mean serum IL-10 levels were significantly higher among patients with CLL. IL-10 level was higher in those who were positive for ZAP-70, Binet stage C, Rai stage III-IV and patients with high scores for CLL prognostic index (≥8). It showed significant positive correlation with the percentage of ZAP-70 expression and significant negative correlation to hemoglobin and platelets count.
Conclusion: Serum IL-10 in patients with CLL at presentation could be used as a prognostic marker for disease progression. Measurement of IL-10 in low resources areas where flowcytometry is not available could be recommended as a substitute investigation.

Full-Text [PDF 684 kb]   (795 Downloads)    
: Original Article | Subject: Adults Hematology & Oncology
Received: 2020/05/1 | Accepted: 2021/02/7 | Published: 2021/05/23

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb